← Back to Search

Observational for Sarcoma

N/A
Recruiting
Led By Hector R. Villarraga, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patients followed at Mayo Clinic and treated for sarcoma with doxorubicin as first-line treatment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, 6 months, 1 year
Awards & highlights

Summary

This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check β€œYes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, 6 months, 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, 6 months, 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in myocardial function - 2D-STE
Changes in myocardial function - 2D-STE vs 2D-LVEF and 3D-LVEF
Changes in myocardial function - 2D-STE vs 3D-STE
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ObservationalExperimental Treatment1 Intervention
Patients receive anthracycline once a day or split between 2-3 days per SOC. Patients undergo 2D-STE throughout the study and have their medical records reviewed on study.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,298 Previous Clinical Trials
3,958,045 Total Patients Enrolled
19 Trials studying Sarcoma
1,845 Patients Enrolled for Sarcoma
Hector R. Villarraga, M.D.Principal InvestigatorMayo Clinic in Rochester
~111 spots leftby Jan 2028